Research

ENDCaP-C Study: Enhanced Neoplasia Detection and Cancer Prevention in Chronic Colitis

CRN West Midlands is the Lead CRN for the ENDCaP-C study (Enhanced Neoplasia Detection and Cancer Prevention in Chronic Colitis: A Multicentre test accuracy study; UKCRN ID: 17739; Chief Investigator: Dr Tariq Iqbal). The study team would like to open an additional 10 sites nationally in order to reach their ambitious recruitment targets and identify more potential PIs. If you or your site might be interested in becoming involved, please review the trial summary and study detail and contact either This e-mail address is being protected from spambots. You need JavaScript enabled to view it or Steve Johnson via This e-mail address is being protected from spambots. You need JavaScript enabled to view it to discuss the study further.

NIHR Specialty Group Newsletters

The NIHR CCRN produces a newsletter for the Specialty Groups.

New Centres Sought for C. difficile Study

alt

The RAPID trial is looking to open more recruitment centres. We are examining the effectiveness of Rifaximin in preventing recurrence of C. difficile infection. Professor Robin Spiller is the Chief Investigator of this NIHR portfolio study (UKCRN ID: 12990), being sponsored by the University of Nottingham.

To express interest and receive more information, please contact Nafisa Boota (Trial Manager, Nottingham Clinical Trials Unit). Telephone: +44 (0)115 884 4924. Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Page 3 of 3